Latest papers

Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.

Centrosomal dysregulation in human metastatic melanoma cell lines.

Mutational inactivation of STAG2 causes aneuploidy in human cancer.

KIT as a therapeutic target in metastatic melanoma.

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.

Abstracts of the 7th European Association of Dermato-Oncology (EADO) Congress. June 20-23, 2011. Nantes, France.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

MicroRNA-155 targets the SKI gene in human melanoma cell lines.

[Melanoma: a new therapeutic era].

Equipoise and the dilemma of randomized clinical trials.

A phase 2 trial of dasatinib in advanced melanoma.

Sentinel-lymph-node biopsy for cutaneous melanoma.

Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.

Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.

Parsing out the complexity of RAF inhibitor resistance.

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.